Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dengue | 8 | 2022 | 107 | 2.080 |
Why?
|
| Fever | 7 | 2022 | 62 | 1.760 |
Why?
|
| Influenza, Human | 5 | 2022 | 92 | 1.050 |
Why?
|
| Puerto Rico | 20 | 2022 | 1413 | 0.920 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2022 | 117 | 0.900 |
Why?
|
| Microcephaly | 1 | 2022 | 21 | 0.740 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 113 | 0.510 |
Why?
|
| Leukopenia | 2 | 2017 | 10 | 0.500 |
Why?
|
| Dengue Virus | 5 | 2022 | 96 | 0.480 |
Why?
|
| Child, Preschool | 8 | 2022 | 1546 | 0.470 |
Why?
|
| Infant | 7 | 2022 | 1175 | 0.460 |
Why?
|
| Child | 11 | 2022 | 3443 | 0.440 |
Why?
|
| Population Surveillance | 5 | 2020 | 246 | 0.420 |
Why?
|
| Adolescent | 14 | 2021 | 6081 | 0.400 |
Why?
|
| Humans | 39 | 2024 | 43102 | 0.390 |
Why?
|
| Female | 25 | 2024 | 24698 | 0.340 |
Why?
|
| Immunoglobulin M | 2 | 2021 | 86 | 0.330 |
Why?
|
| Antibodies, Viral | 3 | 2023 | 306 | 0.330 |
Why?
|
| Retrospective Studies | 12 | 2024 | 2544 | 0.320 |
Why?
|
| Age Distribution | 3 | 2018 | 249 | 0.290 |
Why?
|
| Infant, Newborn | 3 | 2022 | 972 | 0.290 |
Why?
|
| Adult | 17 | 2024 | 13872 | 0.290 |
Why?
|
| Male | 21 | 2024 | 23409 | 0.280 |
Why?
|
| Hospitalization | 4 | 2021 | 485 | 0.280 |
Why?
|
| Young Adult | 10 | 2021 | 5080 | 0.260 |
Why?
|
| Chikungunya virus | 3 | 2023 | 18 | 0.260 |
Why?
|
| RNA, Viral | 2 | 2019 | 321 | 0.260 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 512 | 0.240 |
Why?
|
| Middle Aged | 13 | 2024 | 12222 | 0.240 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 238 | 0.230 |
Why?
|
| Bipolar Disorder | 2 | 2016 | 84 | 0.230 |
Why?
|
| Disease Outbreaks | 2 | 2016 | 175 | 0.220 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 440 | 0.220 |
Why?
|
| Bariatric Surgery | 1 | 2024 | 23 | 0.220 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 22 | 0.210 |
Why?
|
| Pregnancy | 5 | 2022 | 1772 | 0.210 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 278 | 0.210 |
Why?
|
| Incidence | 6 | 2024 | 1078 | 0.200 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2023 | 1 | 0.200 |
Why?
|
| Giant Cell Arteritis | 1 | 2023 | 4 | 0.200 |
Why?
|
| Renal Insufficiency | 1 | 2022 | 19 | 0.190 |
Why?
|
| Postoperative Complications | 1 | 2024 | 263 | 0.190 |
Why?
|
| Amyloidosis | 1 | 2022 | 37 | 0.190 |
Why?
|
| Alternative Splicing | 1 | 2023 | 94 | 0.190 |
Why?
|
| Neurologic Examination | 1 | 2022 | 30 | 0.190 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2022 | 8 | 0.190 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2023 | 58 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 3 | 0.190 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2022 | 1 | 0.180 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 11 | 0.180 |
Why?
|
| Hospitals | 2 | 2020 | 117 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2020 | 1600 | 0.180 |
Why?
|
| Viruses | 1 | 2022 | 39 | 0.180 |
Why?
|
| Laparoscopy | 1 | 2022 | 59 | 0.180 |
Why?
|
| Hyperandrogenism | 1 | 2021 | 5 | 0.170 |
Why?
|
| Panic Disorder | 1 | 2022 | 102 | 0.170 |
Why?
|
| Adenoma | 1 | 2022 | 96 | 0.170 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2021 | 27 | 0.170 |
Why?
|
| Tropical Climate | 1 | 2020 | 23 | 0.160 |
Why?
|
| Triclosan | 1 | 2020 | 5 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 458 | 0.160 |
Why?
|
| Aged | 8 | 2022 | 8214 | 0.160 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 449 | 0.160 |
Why?
|
| Infertility, Female | 1 | 2020 | 24 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2017 | 224 | 0.160 |
Why?
|
| Viral Load | 2 | 2019 | 348 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2019 | 24 | 0.150 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 241 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 218 | 0.150 |
Why?
|
| Stroke | 1 | 2023 | 340 | 0.140 |
Why?
|
| Semen | 1 | 2019 | 57 | 0.140 |
Why?
|
| Cyclonic Storms | 1 | 2020 | 80 | 0.140 |
Why?
|
| Headache | 1 | 2017 | 21 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 23 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2022 | 1759 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 155 | 0.130 |
Why?
|
| Biostatistics | 1 | 2017 | 10 | 0.130 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3156 | 0.130 |
Why?
|
| Sample Size | 1 | 2017 | 28 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 31 | 0.130 |
Why?
|
| Prevalence | 4 | 2022 | 1612 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 125 | 0.130 |
Why?
|
| Character | 1 | 2016 | 2 | 0.120 |
Why?
|
| Time Factors | 2 | 2018 | 1857 | 0.120 |
Why?
|
| Epilepsy | 1 | 2017 | 59 | 0.120 |
Why?
|
| Psychotropic Drugs | 1 | 2016 | 18 | 0.120 |
Why?
|
| Temperament | 1 | 2016 | 36 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 2853 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2017 | 195 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2017 | 575 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 375 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 2018 | 455 | 0.110 |
Why?
|
| Affect | 1 | 2016 | 180 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2017 | 408 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2017 | 549 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2022 | 1604 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 1001 | 0.090 |
Why?
|
| Risk Factors | 4 | 2024 | 3994 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 587 | 0.090 |
Why?
|
| Capillary Fragility | 1 | 2011 | 1 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2011 | 69 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 24 | 0.090 |
Why?
|
| Seasons | 2 | 2021 | 139 | 0.080 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 263 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 830 | 0.070 |
Why?
|
| United States | 4 | 2021 | 5205 | 0.070 |
Why?
|
| Brain | 1 | 2015 | 1472 | 0.070 |
Why?
|
| Mass Screening | 2 | 2022 | 541 | 0.070 |
Why?
|
| Texas | 2 | 2022 | 457 | 0.060 |
Why?
|
| Public Health Practice | 2 | 2016 | 39 | 0.060 |
Why?
|
| Software Validation | 1 | 2024 | 3 | 0.060 |
Why?
|
| Anxiety | 2 | 2022 | 874 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2023 | 27 | 0.050 |
Why?
|
| Rheumatoid Factor | 1 | 2023 | 2 | 0.050 |
Why?
|
| SUMO-1 Protein | 1 | 2023 | 16 | 0.050 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2023 | 15 | 0.050 |
Why?
|
| Blindness | 1 | 2023 | 19 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2023 | 139 | 0.050 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2022 | 14 | 0.050 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2022 | 1 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2023 | 125 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 127 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2022 | 13 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 32 | 0.050 |
Why?
|
| Endemic Diseases | 1 | 2021 | 23 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2023 | 117 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2021 | 87 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2021 | 45 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2022 | 122 | 0.040 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2021 | 25 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2024 | 863 | 0.040 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2021 | 53 | 0.040 |
Why?
|
| Androgens | 1 | 2021 | 106 | 0.040 |
Why?
|
| Parabens | 1 | 2020 | 9 | 0.040 |
Why?
|
| Benzophenones | 1 | 2020 | 11 | 0.040 |
Why?
|
| Influenza A virus | 1 | 2020 | 31 | 0.040 |
Why?
|
| Testosterone | 1 | 2021 | 211 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 51 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 236 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 284 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 322 | 0.040 |
Why?
|
| Vero Cells | 1 | 2019 | 112 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 1154 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2019 | 63 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 193 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 611 | 0.030 |
Why?
|
| Sex Factors | 1 | 2021 | 1028 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 368 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 616 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2019 | 652 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 925 | 0.030 |
Why?
|
| Blood Donors | 1 | 2016 | 20 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 77 | 0.030 |
Why?
|
| Virus Replication | 1 | 2019 | 318 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2016 | 63 | 0.030 |
Why?
|
| Personality Inventory | 1 | 2016 | 82 | 0.030 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2015 | 4 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2016 | 116 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 355 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2016 | 126 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 317 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 282 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 497 | 0.030 |
Why?
|
| Animals | 2 | 2023 | 16992 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 363 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1285 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 2676 | 0.020 |
Why?
|